Bill Walsh Translational Cancer Research Laboratory

The Bill Walsh Translational Cancer Research Laboratory is the research arm of the Medical Oncology Department at Royal North Shore Hospital.

We focus on increasing our understanding of cancer biology and how cancer will behave. We are also working to identify better ways to diagnose cancer.

Through our research we are improving cancer treatment and offering better outcomes for those with the disease.

Lead

Professor Nick Pavlakis BSc, MBBS, MMed (Clin. Epi), PhD, FRACP

Associate Professor, The University of Sydney Northern Clinical School, Faculty of Medicine and Health
Co-head, Bill Walsh Translational Cancer Research Laboratory; Chair, Scientific Advisory Committee, Australasian Lung Cancer Trials Group , Senior Staff Specialist, Dept. of Medical Oncology Royal North Shore

Professor Stephen Clarke OAM, MBBS, PhD, MD, FRACP, FAChPM

Professor, The University of Sydney Northern Clinical School, Faculty of Medicine and Health
Co-head, Bill Walsh Translational Cancer Research Laboratory; Senior Staff Specialist in Dept. Medical Oncology, Royal North Shore Hospital

Associate Professor Helen Wheeler MBBS, FRACP

Co-head, Bill Walsh Translational Cancer Research Laboratory; Senior Staff Specialist, Head Dept. Medical Oncology, Royal North Shore Hospital

Associate Professor, The University of Sydney Northern Clinical School, Faculty of Medicine and Health
Position: Laboratory Research Director, Bill Walsh Translational Cancer Research Laboratory; Co-Lead, Inflammation Flagship, Sydney Vital Translational Cancer Research Centre

People

Dr Emily Colvin BMedSc (Hons), PhD

Appointment: Lecturer, Sydney Medical School (Northern), Faculty of Medicine and Health, The University of Sydney
Position: Proud Family Fellow and Cancer Institute NSW Early Career Fellow
Group Leader: Ovarian Cancer

Associate Professor Connie Diakos BSc(Hons), PhD, MBBS, FRACP, MRACI CChem

Appointment: Conjoint Senior Lecturer, Sydney Medical School (Northern), Faculty of Medicine and Health, The University of Sydney
Position: Research Fellow; Co-lead, Inflammation Flagship, Sydney Vital Translational Cancer Research Centre.
Group Leader: Colorectal Cancer, Neuroendocrine Cancer

Dr Amanda Hudson BSc (Hons), PhD

Appointment: Research Fellow, Sydney Medical School (Northern), Faculty of Medicine and Health, The University of Sydney
Position: The Brain Cancer Group Fellow
Group Leader: Brain Cancer

Ms Shihani Stoner MPhil, MSc, BSc

Appointment: Operations Manager, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney

Operations Manager
Group Leader: Preclinical Pipeline for Advancing Cancer Therapeutics (PACT)

Sooin Byeon – Research Assistant

Taymin du Toit-Thompson – PhD Student

Farah Abu Al-Hial - Research Officer

Nada Cheikh-Ali - Clinical Researcher

Heidi Tsang - Clinical Research Associate

Carolyn Kwong - Clinical Research Officer

Saurabh Satijah - Research Affiliate

Julius Kim - Mark Hughes Brain Cancer Research Fellow

Hasanthi De Silva - Senior Research Officer

Liz Millar - Research Assistant

Sara Mokhtar - Research Assistant

Narjis Fatima - Postdoctoral Research Associate

Hye Soo Lee - Medical Placement Student

Emma Woodlock - Honours Student

Krishna Kotecha - PhD Student

Tina Kassiou - Honours Student

Joe Wei - Researcher

Network

Sydney Vital

Projects

Brain Cancer:

Teaching an Old Drug New Tricks: Can we repurpose an old drug as a new brain cancer treatment?
The immuno-coagulome: an untapped pathway for new therapeutics in glioma
Investigating how glioblastoma tumours change over time to become resistant to treatment
Unravelling the tumour micro-environment to combat brain cancer
Laying the foundations for improved treatments for IDH-mutated glioma
The interaction between coagulation, angiogenesis and inflammatory pathways in glioblastoma
MHF Brain Cancer PACT: Mark Hughes Foundation Collaborative Brain Cancer Pre-clinical pipeline for Advancing Cancer Therapeutics
Development of non-invasive monitoring for brain tumour recurrence and treatment resistance
A new class of theranostics for malignant brain cancer
Radiosensitisation of high-grade gliomas by modulating glucose metabolism
New Horizons: Therapeutic applications for medicinal cannabis in the treatment of brain cancer

Colorectal Cancer:

The role ofIinflammation in colorectal cancer
Identifying prognostic protein markers in colorectal cancer tumour
Exploring a new nanotechnology strategy for the neo-adjuvant treatment of colorectal cancer by photodynamic therapy and ionising radiation

Lung Cancer:

Investigating patterns of drug resistance in ALK rearranged non-small cell lung cancer
Exploring methods to improve efficacy of immunotherapy in non-small cell lung cancer
Identification of biomarkers for non-small cell lung cancer
Chemotherapy resistance in non-small cell lung cancer
The exhaled breath condensate proteome: a promising source of biomarkers for lung cancer

Mesothelioma:

Improved treatment for mesothelioma: Can cannabinoids address this unmet need?

Neuroendocrine Tumours:

The role of dual PET scans in understanding neuroendocrine tumour behaviour
Analysing PET scans for neuroendocrine tumours

Ovarian Cancer:

Evaluation of lysyl oxidase inhibitors as a new treatment for ovarian cancer
Investigating the role of long non-coding RNA (ribonucleic acid) in the ovarian cancer microenvironment
Improving ovarian cancer treatment using nanoparticles

Pancreatic Cancer:

Biomarker identification for pancreatic cancer diagnosis
Biomarker identification for pancreatic cancer prognosis.
Identification of new drug targets for pancreatic cancer treatment
Understanding the role of tumour microenvironment in pancreatic cancer progression